Edition:
United Kingdom

Infinity Pharmaceuticals Announces Royalty Monetization Of COPIKTRA For $30 Mln Gross Proceeds


Wednesday, 6 Mar 2019 

March 6 (Reuters) - Infinity Pharmaceuticals Inc ::INFINITY PHARMACEUTICALS ANNOUNCES ROYALTY MONETIZATION OF COPIKTRA FOR $30 MILLION GROSS PROCEEDS.INFINITY PHARMACEUTICALS INC - ANNOUNCED ROYALTY MONETIZATION WITH HEALTHCARE ROYALTY PARTNERS (HCR) FOR RIGHT TO RECEIVE CERTAIN ROYALTY PAYMENTS.INFINITY PHARMACEUTICALS INC - ROYALTY PAYMENTS BASED ON WORLDWIDE ANNUAL NET SALES OF COPIKTRA (DUVELISIB), PAYABLE BY VERASTEM.INFINITY PHARMACEUTICALS - UNDER AGREEMENT, HCR HAS AGREED TO PAY CO A $30 MILLION UPFRONT PAYMENT AND UP TO $20 MILLION IN POTENTIAL MILESTONE PAYMENTS.INFINITY PHARMACEUTICALS INC - IN CONNECTION WITH ROYALTY MONETIZATION, INFINITY ENTERED INTO AN AMENDMENT OF ITS LICENSE AGREEMENT WITH TAKEDA.INFINITY PHARMACEUTICALS - AS PER AMENDMENT OF LICENSE AGREEMENT WITH TAKEDA, TAKEDA HAS AGREED TO RECEIVE A PORTION OF TOTAL INVESTMENT AMOUNT.